Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy
Phase 2
140
about 7 years
30+
Male only
1 site in NE
What this study is about
This trial is testing whether a treatment with abiraterone and prednisone, plus standard hormone therapy, is better than standard hormone therapy alone for prostate cancer patients whose lymph nodes show signs of the disease using a special imaging test. The goal is to see if this new treatment leads to longer survival without the cancer coming back compared to the usual treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Hormone therapy
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
hormone therapy, abiraterone, prednisone
oral
Secondary: Evaluate 5-year overall survival, Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (FACT-P), Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (IPSS), Evaluate local progression-free survival (i.e., failure-free survival excluding biochemical failure)., Evaluate locoregional progression-free survival (i.e., failure-free survival excluding biochemical failure)., Toxicity in both arms from 3 months to 2 years post-ADT.
radiation
Oncology